Predicting response to opiate antagonists and placebo in the treatment of pathological gambling

Jon E. Grant, Suck Won Kim, Eric Hollander, Marc N. Potenza

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Rationale: Although opiate antagonists have shown promise in the treatment of pathological gambling (PG), individual responses vary. No studies have systematically examined predictors of medication treatment outcome in PG. Understanding clinical variables related to treatment outcome should help generate treatment algorithms for PG. Objective: We sought to identify clinical variables associated with treatment outcome in PG subjects receiving opiate antagonists. Materials and methods: Two hundred eighty-four subjects [137 (48.2%) women] with DSM-IV PG were treated in one of two double-blind placebo-controlled trials (16 weeks of nalmefene or 18 weeks of naltrexone). Gambling severity was assessed with the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) with positive response defined as ≥35% reduction in PG-YBOCS score for at least 1 month by study endpoint. Depression, anxiety, and psychosocial functioning were included in stepwise logistic regression analyses designed to identify clinical factors independently associated with treatment response. Results: The clinical variable most strongly associated with a positive response to an opiate antagonist was a positive family history of alcoholism (p=0.006). Among individuals receiving higher doses of opiate antagonists (i.e., nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day), intensity of gambling urges (PG-YBOCS urge subscale) was associated with a positive response on a trend level (p=0.036). Among individuals receiving placebo, younger age was associated, on a trend level, with positive treatment outcome (p=0.012). Conclusions: A family history of alcoholism appears to predict response to an opiate antagonist in PG. Future research is needed to identify specific factors (e.g., genetic) mediating favorable responses.

Original languageEnglish (US)
Pages (from-to)521-527
Number of pages7
JournalPsychopharmacology
Volume200
Issue number4
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Opiate Alkaloids
Gambling
Placebos
Therapeutics
Naltrexone
Alcoholism

Keywords

  • Addiction
  • Impulse control disorders
  • Impulsivity
  • Opiate antagonists
  • Pharmacotherapy
  • Placebo

ASJC Scopus subject areas

  • Pharmacology

Cite this

Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. / Grant, Jon E.; Kim, Suck Won; Hollander, Eric; Potenza, Marc N.

In: Psychopharmacology, Vol. 200, No. 4, 11.2008, p. 521-527.

Research output: Contribution to journalArticle

Grant, Jon E. ; Kim, Suck Won ; Hollander, Eric ; Potenza, Marc N. / Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. In: Psychopharmacology. 2008 ; Vol. 200, No. 4. pp. 521-527.
@article{1ff9253dee684da78d679c8e1e988eb1,
title = "Predicting response to opiate antagonists and placebo in the treatment of pathological gambling",
abstract = "Rationale: Although opiate antagonists have shown promise in the treatment of pathological gambling (PG), individual responses vary. No studies have systematically examined predictors of medication treatment outcome in PG. Understanding clinical variables related to treatment outcome should help generate treatment algorithms for PG. Objective: We sought to identify clinical variables associated with treatment outcome in PG subjects receiving opiate antagonists. Materials and methods: Two hundred eighty-four subjects [137 (48.2{\%}) women] with DSM-IV PG were treated in one of two double-blind placebo-controlled trials (16 weeks of nalmefene or 18 weeks of naltrexone). Gambling severity was assessed with the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) with positive response defined as ≥35{\%} reduction in PG-YBOCS score for at least 1 month by study endpoint. Depression, anxiety, and psychosocial functioning were included in stepwise logistic regression analyses designed to identify clinical factors independently associated with treatment response. Results: The clinical variable most strongly associated with a positive response to an opiate antagonist was a positive family history of alcoholism (p=0.006). Among individuals receiving higher doses of opiate antagonists (i.e., nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day), intensity of gambling urges (PG-YBOCS urge subscale) was associated with a positive response on a trend level (p=0.036). Among individuals receiving placebo, younger age was associated, on a trend level, with positive treatment outcome (p=0.012). Conclusions: A family history of alcoholism appears to predict response to an opiate antagonist in PG. Future research is needed to identify specific factors (e.g., genetic) mediating favorable responses.",
keywords = "Addiction, Impulse control disorders, Impulsivity, Opiate antagonists, Pharmacotherapy, Placebo",
author = "Grant, {Jon E.} and Kim, {Suck Won} and Eric Hollander and Potenza, {Marc N.}",
year = "2008",
month = "11",
doi = "10.1007/s00213-008-1235-3",
language = "English (US)",
volume = "200",
pages = "521--527",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Predicting response to opiate antagonists and placebo in the treatment of pathological gambling

AU - Grant, Jon E.

AU - Kim, Suck Won

AU - Hollander, Eric

AU - Potenza, Marc N.

PY - 2008/11

Y1 - 2008/11

N2 - Rationale: Although opiate antagonists have shown promise in the treatment of pathological gambling (PG), individual responses vary. No studies have systematically examined predictors of medication treatment outcome in PG. Understanding clinical variables related to treatment outcome should help generate treatment algorithms for PG. Objective: We sought to identify clinical variables associated with treatment outcome in PG subjects receiving opiate antagonists. Materials and methods: Two hundred eighty-four subjects [137 (48.2%) women] with DSM-IV PG were treated in one of two double-blind placebo-controlled trials (16 weeks of nalmefene or 18 weeks of naltrexone). Gambling severity was assessed with the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) with positive response defined as ≥35% reduction in PG-YBOCS score for at least 1 month by study endpoint. Depression, anxiety, and psychosocial functioning were included in stepwise logistic regression analyses designed to identify clinical factors independently associated with treatment response. Results: The clinical variable most strongly associated with a positive response to an opiate antagonist was a positive family history of alcoholism (p=0.006). Among individuals receiving higher doses of opiate antagonists (i.e., nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day), intensity of gambling urges (PG-YBOCS urge subscale) was associated with a positive response on a trend level (p=0.036). Among individuals receiving placebo, younger age was associated, on a trend level, with positive treatment outcome (p=0.012). Conclusions: A family history of alcoholism appears to predict response to an opiate antagonist in PG. Future research is needed to identify specific factors (e.g., genetic) mediating favorable responses.

AB - Rationale: Although opiate antagonists have shown promise in the treatment of pathological gambling (PG), individual responses vary. No studies have systematically examined predictors of medication treatment outcome in PG. Understanding clinical variables related to treatment outcome should help generate treatment algorithms for PG. Objective: We sought to identify clinical variables associated with treatment outcome in PG subjects receiving opiate antagonists. Materials and methods: Two hundred eighty-four subjects [137 (48.2%) women] with DSM-IV PG were treated in one of two double-blind placebo-controlled trials (16 weeks of nalmefene or 18 weeks of naltrexone). Gambling severity was assessed with the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) with positive response defined as ≥35% reduction in PG-YBOCS score for at least 1 month by study endpoint. Depression, anxiety, and psychosocial functioning were included in stepwise logistic regression analyses designed to identify clinical factors independently associated with treatment response. Results: The clinical variable most strongly associated with a positive response to an opiate antagonist was a positive family history of alcoholism (p=0.006). Among individuals receiving higher doses of opiate antagonists (i.e., nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day), intensity of gambling urges (PG-YBOCS urge subscale) was associated with a positive response on a trend level (p=0.036). Among individuals receiving placebo, younger age was associated, on a trend level, with positive treatment outcome (p=0.012). Conclusions: A family history of alcoholism appears to predict response to an opiate antagonist in PG. Future research is needed to identify specific factors (e.g., genetic) mediating favorable responses.

KW - Addiction

KW - Impulse control disorders

KW - Impulsivity

KW - Opiate antagonists

KW - Pharmacotherapy

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=52649104059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649104059&partnerID=8YFLogxK

U2 - 10.1007/s00213-008-1235-3

DO - 10.1007/s00213-008-1235-3

M3 - Article

C2 - 18581096

AN - SCOPUS:52649104059

VL - 200

SP - 521

EP - 527

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -